prusogliptin + dapagliflozin + metformin

This drug is a **combination therapy** comprising three agents: prusogliptin, dapagliflozin, and metformin. Each component acts via a distinct mechanism to improve glycemic control in patients with type 2 diabetes mellitus. - **Dapagliflozin** is a sodium-glucose co-transporter-2 (SGLT2) inhibitor that lowers blood glucose by promoting renal glucose excretion. - **Metformin** is a biguanide that primarily reduces hepatic glucose production and improves insulin sensitivity. - **Prusogliptin** is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which increases incretin levels (GLP-1 and GIP), enhancing insulin secretion and reducing glucagon levels in a glucose-dependent manner. The combination is intended for patients with type 2 diabetes, particularly those inadequately controlled with monotherapy or dual therapy, providing complementary and synergistic effects on glycemic reduction and potential benefits such as modest weight loss, improved insulin sensitivity, and possible cardiovascular protection. Specific information on the triple combination with **prusogliptin** is not widely reported in major clinical sources; most available studies describe similar combinations with alternative DPP-4 inhibitors like linagliptin or saxagliptin[4][6]. Nonetheless, the rationale and mechanisms are analogous.

Other names

Prusogliptin, Dapagliflozin and Metformin Extended-Release Tablets